In contrast, TKIs have shown limited efficacy in tumors where mutations in EGFR are not present, such as NSCLC with wild-type EGFR (102), and where EGFR-activating mutations are less common, such as in mCRC and SCCHN (9–11, 103, 104). This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.